Results 11 to 20 of about 1,610,894 (277)

Radiation Therapy Combined With Checkpoint Blockade Immunotherapy for Metastatic Undifferentiated Pleomorphic Sarcoma of the Maxillary Sinus With a Complete Response [PDF]

open access: yesFrontiers in Oncology, 2018
Background: Undifferentiated pleomorphic sarcoma (UPS) of the maxillary sinus is an extremely rare malignancy of the head and neck. Surgery is the mainstay of treatment for UPS; however, proximity to vital structures makes it challenging to achieve ...
Kripa Guram   +11 more
doaj   +2 more sources

A Silver‐Induced Absorption Red‐Shifted Dual‐Targeted Nanodiagnosis‐Treatment Agent for NIR‐II Photoacoustic Imaging‐Guided Photothermal and ROS Simultaneously Enhanced Immune Checkpoint Blockade Antitumor Therapy

open access: yesAdvanced Science, 2023
Tumor metastasis remains a leading factor in the failure of cancer treatments and patient mortality. To address this, a silver‐induced absorption red‐shifted core‐shell nano‐particle is developed, and surface‐modified with triphenylphosphonium bromide ...
Yulong Bai   +8 more
doaj   +3 more sources

Immune checkpoint blockade for glioblastoma: Preclinical activity of single agent and combinatorial therapy. [PDF]

open access: yesJournal of Clinical Oncology, 2014
2084 Background: Outcome for glioblastoma (GBM) remains dismal and innovative treatment strategies are desperately needed. Growing data support the contribution of local and systemic immune checkpoint molecules mediating immunosuppression by GBM tumors.
David A. Reardon   +12 more
  +5 more sources

DNA replication is required for the checkpoint response to damaged DNA in Xenopus egg extracts. [PDF]

open access: yes, 2002
Alkylating agents, such as methyl methanesulfonate (MMS), damage DNA and activate the DNA damage checkpoint. Although many of the checkpoint proteins that transduce damage signals have been identified and characterized, the mechanism that senses the ...
Lindsay, Howard D.   +3 more
core   +5 more sources

Chemotherapeutic and targeted agents can modulate the tumor microenvironment and increase the efficacy of immune checkpoint blockades [PDF]

open access: yesMolecular Cancer, 2021
AbstractThe development of immune checkpoint blockade (ICB)-based immunotherapy has dramatically changed methods of cancer treatment. This approach triggers a durable treatment response and prolongs patients' survival; however, not all patients can benefit.
Jun-Yan Li   +4 more
openaire   +3 more sources

Supplementary Figure from A Pan-Cancer Immunogenomic Atlas for Immune Checkpoint Blockade Immunotherapy

open access: yes, 2022
Supplementary Figure from A Pan-Cancer Immunogenomic Atlas for Immune Checkpoint Blockade ...
Jing Wang (6206297)   +5 more
core   +5 more sources

Supplementary Figure from Loss of LRRC33-Dependent TGFβ1 Activation Enhances Antitumor Immunity and Checkpoint Blockade Therapy

open access: yes, 2022
Supplementary Figure from Loss of LRRC33-Dependent TGFβ1 Activation Enhances Antitumor Immunity and Checkpoint Blockade ...
Timothy A. Springer (15129090)   +2 more
core   +6 more sources

Personalized Ultrafractionated Stereotactic Adaptive Radiotherapy (PULSAR) in Preclinical Models Enhances Single-Agent Immune Checkpoint Blockade

open access: yesInternational Journal of Radiation Oncology*Biology*Physics, 2021
Harnessing the immune-stimulatory effects of radiation by combining it with immunotherapy is a promising new treatment strategy. However, more studies characterizing immunotherapy and radiation dose scheduling for the optimal therapeutic effect is essential for designing clinical trials.A new ablative radiation dosing scheme, personalized ...
Casey Moore   +11 more
openaire   +3 more sources

Agent-Based Modelling Reveals the Role of the Tumor Microenvironment on the Short-Term Success of Combination Temozolomide/Immune Checkpoint Blockade to Treat Glioblastoma

open access: yesThe Journal of Pharmacology and Experimental Therapeutics, 2023
Glioblastoma is the most common and deadly primary brain tumor in adults. All glioblastoma patients receiving standard-of-care surgery-radiotherapy-chemotherapy (i.e., temozolomide (TMZ)) recur, with an average survival time of only 15 months. New approaches to the treatment of glioblastoma, including immune checkpoint blockade and oncolytic viruses ...
Anudeep Surendran   +6 more
openaire   +3 more sources

TIGIT and PD-1 Immune Checkpoint Pathways Are Associated With Patient Outcome and Anti-Tumor Immunity in Glioblastoma

open access: yesFrontiers in Immunology, 2021
Glioblastoma (GBM) remains an aggressive brain tumor with a high rate of mortality. Immune checkpoint (IC) molecules are expressed on tumor infiltrating lymphocytes (TILs) and promote T cell exhaustion upon binding to IC ligands expressed by the tumor ...
Itay Raphael   +22 more
doaj   +1 more source

Home - About - Disclaimer - Privacy